
|Articles|June 9, 2021
ODs: Here's what your patients tweeted about you in May 2021 pt. 2
Author(s)Brooke Henson, Editor
Find out what your patients are tweeting about you
Advertisement
Advertisement
Related to this article

Eric Schmidt, OD, FAAO, presented his poster "Patient-Reported Blurred Vision Improvement with Cyclosporine 0.1%/PFBP in Dry Eye Disease with Severe Central Corneal Staining: Phase 3 Pool" at AAOpt 2026.

Aflibercept 8 mg cut RVO injections by up to 3 over 64 weeks in QUASAR, while a pair of additional posters show Amsler gaps in AMD and BRAO-linked stroke risk.

Host Hamza Shah, OD, MS, FAAO, is joined by Cory Lappin, OD, MS, FAAO, to discuss dynamic muscle stimulation for dry eye, spurred by a paper on improving blinking in dry eye patients.

A young woman had years of headaches, dizziness, and intolerance of her phone despite normal routine eye examinations. A modest prism gave her immediate relief.

Raman Bhakhri, OD, FAAO, details a session given with Denise Skiadopoulos, OD, FAAO, during the annual AAOpt meeting in Anaheim, California.

Sherrol Reynolds, OD, FAAO, details her session "GLP-1RAs and Ocular Health: AOA Guidance for Optometric Practice 2025" during AAOpt 2026.

Phil Rainey, OD, MPH, FAAO, states that the recent parameter expansion of Johnson & Johnson's Acuvue Oasys Max 1-Day and Oasys 1-Day has been a game changer for his practice.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
AAOpt 2026: Demodex tied to worse MGD as dry eye questionnaires miss blepharitis
2
AAOpt 2026: The real-world impact of treatment switch to latanoprostene bunod
3
AAOpt 2026: Aflibercept 8 mg extends RVO dosing as Amsler misses AMD damage
4
AAOpt 2026: Acuvue Oasys 1-Day lenses as an optimal option for athletes
5

